AbbVie Reports Strong Phase 2 Data in Ovarian Cancer
North Chicago, Illinois | April 12, 2026 AbbVie has announced late-breaking Phase 2 clinical trial results demonstrating strong efficacy...
AbbVie
Advertisement
Canada Issues Positive Reimbursement Recommendation for Skyrizi in Ulcerative Colitis
Montréal, 28 November 2025 In a major development for inflammatory bowel disease (IBD) care, Canada’s Drug Agency (AMC) has...
AbbVie’s Epkinly Gets FDA Nod for Follicular Lymphoma Combo
NORTH CHICAGO, IL – November 18, 2025 — AbbVie announced that the U.S. Food and Drug Administration (FDA) has...
AbbVie Raises 2025 Outlook as Skyrizi and Rinvoq Surge
NORTH CHICAGO, Ill., November 2, 2025 — AbbVie Inc. (NYSE: ABBV), a global biopharmaceutical leader, has raised its annual...
FDA Updates RINVOQ® Label for Inflammatory Bowel Disease Use
NORTH CHICAGO, Illinois, October 13, 2025 – AbbVie Inc. (NYSE: ABBV) announced that the U.S. Food and Drug Administration...
Advertisements
AbbVie Submits BLA for Pivekimab Sunirine to FDA for Rare Blood Cancer
North Chicago, IL – September 30, 2025 – AbbVie (NYSE: ABBV) announced the submission of a Biologics License Application...
AbbVie Seeks FDA Approval for Tavapadon to Treat Parkinson’s Disease
North Chicago, Ill., September 26, 2025 – AbbVie (NYSE: ABBV) announced the submission of a New Drug Application (NDA)...
Private Equity Firm, THL to Acquire Clinical Trial Site Network, Headlands Research from KKR
Lake Worth, FL. & New York, August 23, 2025 – Thomas H. Lee Partners (THL) has entered into a...
mRNA Patent Dispute Resolved: BioNTech, CureVac, and GSK Strike $370M Licensing Deal
August 8, 2025 — London, UK. BioNTech SE has reached an agreement with CureVac to receive a non-exclusive license...
AbbVie Completes $2.1B Acquisition of Capstan Therapeutics, Advancing In Vivo CAR-T Innovation
NORTH CHICAGO, IL. and SAN DIEGO, CA, August 19, 2025 – AbbVie (NYSE: ABBV) and Capstan Therapeutics, Inc. (“Capstan”),...
Advertisement
